A pharmaceutical composition for use in the treatment or prevention of cancer in a HLA-A * 3303 positive subject, which includes a peptide consisting of an amino acid sequence (1) or (2): (1) an amino acid sequence selected from: Leu Ser His Leu Gln Met His Ser Arg (SEC. ID. No. 2), Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEC. ID. No. 3) and 10 Thr Ser Glu Lys Pro Phe Ser Cys Arg ( SEQ ID NO. 5)； (2) an amino acid sequence selected from the SEC. ID. No. 2, SEC. ID. No. 3 and SEC. ID. No. 5, where one amino acid is substituted with another amino acid, provided that the amino acid in position 2 is any of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp, and that the amino acid in position 9 is Arg , where the peptide consisting of an amino acid sequence (2) has the capacity to bind to an HLA-A * 3303 molecule and has the capacity to induce CTL, and where the cancer is any of a hematopoietic tumor, such as leukemia, myelodysplastic syndrome, multiple myeloma or malignant lymphoma, and a solid cancer, such as gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer , cervical cancer or ovarian cancer.Una composición farmacéutica para uso en el tratamiento o la prevención de un cáncer en un sujeto positivo a HLA-A*3303, que incluye un péptido consistente en una secuencia de aminoácidos (1) o (2): (1) una secuencia de aminoácidos seleccionada entre: Leu Ser His Leu Gln Met His Ser Arg (SEC. ID. Nº 2), Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEC. ID. Nº 3) y 10 Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEC. ID. Nº 5)； (2) una secuencia de aminoácidos seleccionada entre la SEC. ID. Nº 2, la SEC. ID. Nº 3 y la SEC. ID. Nº 5, en donde un aminoácido está substituido con otro aminoácido, siempre que el aminoácido en la posición 2 sea cualquiera de Ala, Ile, Leu, Val, Phe, Tyr, Ser y Asp, y que el aminoácido en la posición 9 sea Arg, donde el péptido consistente en una secuencia de aminoácidos (2) tiene
